Albany, NY -- (SBWIRE) -- 02/22/2018 -- Induced pluripotent stem cells (iPSCs or iPS cells) are a form of pluripotent stem cells, generated directly from somatic (adult) cells. Pluripotent stem cells have significant potential in regenerative medicine. These possess the potential and capability to form various types of adult cells such as liver, heart, neurons, and pancreatic cells. These cells can proliferate indeterminately and can be used to repair or replace cells that are damaged due to diseases. In 2006, Shinya Yamanaka's lab (Kyoto, Japan) for the first time successfully converted somatic (adult) cells into pluripotent stem cells. In 2012, Shinya Yamanaka along with Sir John Gurdon, was awarded the Nobel Prize for "the discovery of reprogramming mature cells to convert to pluripotent stem cells." Embryonic stem cells are the most recognized type of pluripotent stem cells. The embryonic stem cells are generated by the destruction or manipulation of pre-implantation stage embryo. This led to much controversy and ethical issues regarding their use. Moreover, embryonic stem cells can be derived only from embryos, hence it has been infeasible to produce patient-matching embryonic stem cell lines. Induced pluripotent stem cells can be generated directly from adult tissues, bypassing the need for embryos and enabling the creation of a patient-matched pluripotent stem cell line for every individual.
Request for Sample Copy of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30530
The global induced pluripotent stem cells market is developing rapidly. The primary reason for inclination toward usage of induced pluripotent stem cells is their ability to make any cell or tissue required by the body to defend or combat diseases such as leukemia, spinal cord injury, heart disease, and diabetes. These cells can be modified or customized as per a patient's genetic makeup, providing a perfect match. Additionally, induced pluripotent stem cells help in understanding human development at an early stage, thus offering an opportunity to develop rejection-proof, customized cells and tissues for efficacious transplantation. Increasing interest among scientists and researchers in this field and varied applications in disease treatment and other aspects is expected to drive the market. Furthermore, increased funding by governments and private sector and growing industry focus on induced pluripotent stem cells and related research, clinical applications, and awareness among the people about stem cells and induced pluripotent stem cells are likely to boost market growth during the forecast period. However, factors such as increasing costs associated with the treatment and reprogramming of cells, lengthy processes, and ethical issues hamper the growth of the market. Moreover, concerns such as low efficiency and proliferation rates, possible tumor risk, premature cell death, and incomplete programming are other factors that restrain the global induced pluripotent stem cell market.
The global induced pluripotent stem cells market can be segmented based on application, derived cell type, end-user, and region. In terms of application, the market can be divided into drug development, regenerative medicine, toxicity testing, and academic research. Based on derived cell type, the market can be segmented into fibroblasts, amniotic cells, hepatocytes, keratinocytes, and others. In terms of end-user, the market can be categorized into research organizations and hospitals.
Request Table of Content of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30530
Geographically, the induced pluripotent stem cells market can be segmented into five major regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global market, followed by Europe. Presence of definite business models in Canada and the U.S. contribute to the growth of the market in the region. Additionally, organizations are investing in research activities involving iPSCs. For example, the California Institute for Regenerative Medicine (CIRM) has encouraged research institutes to provide funds for the clinical focus on iPSC and their translation into clinical therapies. This is anticipated to contribute to the growth of the market in North America. The induced pluripotent stem cells market in countries in Asia Pacific is expected to witness rapid growth. Increasing number of research projects in countries such as Japan, Singapore, and Australia is anticipated to propel the market. Therefore, Asia Pacific and Latin America are projected to drive the global induced pluripotent stem cells market.
Key players in the global induced pluripotent stem cells market are Astellas Pharma Inc., Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics International, Inc.), EVOTEC, Japan Tissue Engineering Co., Ltd, ViaCyte, Inc., and Vericel Corporation, among others.
Request For Discount On This Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30530